Answers are grounded in this paper and cite their sources.
INTRODUCTION Tau PET informs Alzheimer's disease (AD) staging but is limited by cost and access. Plasma phosphorylated‐to‐nonphosphorylated tau217 ratio (pTau217R) predicts amyloid and tau positron emission tomography (PET), while cerebrospinal fluid (CSF) MTBR‐tau243 (tryptic form) and its endogenous form (eMTBR‐tau243) reflect tau pathology. We evaluated whether combining them improves tau PET prediction in amyloid‐positive early AD. METHODS In the phase III lecanemab trial, plasma pTau217R was available for 242 participants, CSF markers for 80, and both for 57. Tau PET used [ 18 F]MK6240. Stochastic gradient boosting models included demographics and apolipoprotein E (APOE) ε4, with performance assessed via repeated cross‐validation. RESULTS Plasma pTau217R matched CSF eMTBR‐tau243 and outperformed MTBR‐tau243. Combining pTau217R with either CSF marker improved prediction ( R 2 to 0.74; AUROC to 0.94) and could reduce PET use by 58%–80% for prescreening at 10% false negatives. DISCUSSION Plasma pTau217R plus CSF eMTBR‐tau243 predict regional tau burden and may reduce reliance on tau PET in early AD trials. CLINICALTRIALS.GOV IDENTIFIERS NCT03887455 (ClarityAD) Highlights Combining plasma pTau217R and CSF eMTBR‑tau243 improves tau PET prediction. The model predicts regional tau PET SUVRs with high accuracy across key regions. Single‐marker models show pTau217R and eMTBR‐tau243 outperform MTBR‐tau243. PET‑sparing triage reduces scan burden by up to 80% at 10% false negatives. Stochastic gradient boosting enables region‐specific tau PET prediction in one unified model.
No takes yet. Share an insight, caveat, or question.
Devanarayan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: